Última actualización 24 de agosto de 2026
Key finding
The chronic eGFR-cystatin C slope in the canagliflozin group was -0.4 (95% CI, -2.6 to 1.8) ml/min per 1.73 m²/year.
The CANPIONE study investigated the effects of canagliflozin on type 2 diabetic patients with microalbuminuria in a Japanese population, finding significant reductions in body weight and HbA1c levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The CANPIONE study investigated the effects of canagliflozin on type 2 diabetic patients with microalbuminuria in a Japanese population, finding significant reductions in body weight and HbA1c levels.
These findings are significant as they highlight the potential benefits of canagliflozin for managing weight and blood sugar in type 2 diabetes patients, particularly those with microalbuminuria. However, the observed decline in renal function markers raises concerns about long-term kidney health, necessitating careful monitoring in clinical practice.
The study's population was limited to a specific ethnic group, affecting generalizability. The sample size may not be large enough to detect rare complications. Long-term effects of canagliflozin on renal function were not fully explored.
Published in
Publication details and source links for this paper.
Satoshi M, Hiddo JH, Dick DZ, et al. Canagliflozin in Type 2 Diabetic Patients with Microalbuminuria in Japanese Population (CANPIONE) Study. Kidney International Reports. 2026;11(5):106374. doi:10.1016/j.ekir.2026.106374
Canagliflozin reduced body weight and BMI.
Chronic eGFR-cystatin C slope decreased by -0.4 ml/min per 1.73 m²/year.
Chronic eGFR-creatinine slope decreased by -4.9 ml/min per 1.73 m²/year.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Canagliflozin and Annual rate of change in eGFR, BMI, Body weight, and 8 more.
This study contributes evidence to
Primary intervention
Canagliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
11
Evidence pairs
698
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Canagliflozin → Annual rate of change in eGFR
Canagliflozin → Annual rate of change in eGFR
Canagliflozin → Change in arterial stiffness progression
Canagliflozin → Change in arterial stiffness progression
Canagliflozin → Diabetic microvascular complication multimorbidity
Canagliflozin → Diabetic microvascular complication multimorbidity
Canagliflozin → Diabetic nephropathy incidence
Canagliflozin → Diabetic nephropathy incidence
Canagliflozin → Diabetic neuropathy incidence
Canagliflozin → Diabetic neuropathy incidence
Canagliflozin → Diabetic retinopathy incidence
Canagliflozin → Diabetic retinopathy incidence
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
3 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 19 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Diabetic nephropathy incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
